Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: 0.31 + injectable + web  Related to the article below (Last Update: 8/5/2008)

Cubist Pharmaceuticals Reports First $100 Million Revenue Quarter ...
WELT ONLINE, Germany - Jul 17, 2008
For the second quarter ended June 30, 2008, Cubist?s net revenues from CUBICIN? (daptomycin for injection) increased 46% from the prior year, ...CBST - DYAX
ProEx Reports Second Quarter Results
Canada NewsWire (press release), Canada - Jul 29, 2008
Information is also accessible on the Company's web site at www.proexenergy.com. << PROEX ENERGY LTD. BALANCE SHEETS (Unaudited) June 30, December 31, ...TSE:PXE
Source: Google News

Residential Segregation and Injection Drug Use Prevalence Among Black Adults in US Metropolitan … -
HLF Cooper, SR Friedman, B Tempalski, R Friedman - American Journal of Public Health, 2007 - Am Public Health Assoc
... associated with the prevalences of overdose deaths (R = 0.31; P = .003 ... factors to
guide structural intervention: predictors of injection drug use ... Du Bois WEB. ...

Using injectable carriers of laser-polarized noble gases for enhancing NMR and MRI -
BM Goodson - Concepts in Magnetic Resonance, 1999 - doi.wiley.com
Page 1. Using Injectable Carriers of ... Next, recent examples of ex- perimental work
are shown where the utility of injectable noble gas carriers was investigated. ...

[PDF] at AMCP?s 2007 Educational Conference
M INFARCTION, H FAILURE - amcp.org
... 17 academic and community sites across the country for this Web-based sur ... differences
were observed for bleeding events (oral=0.28%, injectable= 0.31%, P=0.7453 ...
-

Eliciting Preferences for Hypothetic Health States from Patients: A Comparison between Time Trade- …
S ABALLEA, S CURE, J CHANCELLOR, ROB SHELDON, N … - papers.ssrn.com
... for inhaled insulin were greater than their injectable insulin counterparts ... TTO values
ranged from 0.07 to 0.31 (p<0.05 ... To go to SSRN's main web site (www.ssrn ...

Aspirin lowers blood pressure in patients with renovascular hypertension -
M Imanishi, M Kawamura, S Akabane, Y Matsushima, M … - Hypertension, 1989 - Am Heart Assoc
... org located on the World Wide Web at: The ... rep- resentative PG synthesis inhibitor,
is not injectable for clinical ... PGE 2 concen- tration, 1.50?0.31; right side ...

Negative effects of vitamin K preparations on glucuronyl transferase activity -
B Jones - Pediatrics, 1967 - Am Acad Pediatrics
... http://www.pediatrics.org the World Wide Web at: The online version of this ... name
exclusively and there is n indication of whether the injectable solution or ...
-

Role of intravascular coagulation and granulocytes in lung vascular injury after bone marrow … -
PS Barie, AB Malik - Circulation Research, 1982 - Am Heart Assoc
... http://circres.ahajournals.org located on the World Wide Web at: The online ... P^ was
increased to 20.3 ? 1.8 torr after the BMS injection (Table 3 ... 2.01 ? 0.31 ...

Glycine betaine and its use -
J Messadek - US Patent 6,855,734, 2005 - freepatentsonline.com
... Article from Entrez-PubMed web page entitled: antiplatelet and ... at T.sub.0, followed
by subcutaneous injection of glycine ... 0.31 100 mg/kg Heparin 2 mg/kg 6.20 ...

Acidic polysaccharides crosslinked with polycarboxylic acids and their uses -
TT Nguyen - US Patent 5,690,961, 1997 - freepatentsonline.com
... The injectable solution may contain materials in addition to the crosslinked hyaluronic
acid. ... 7 2300 DETPAA 0.15 0.42 gelled 8 2100 BTDA 0.10 0.31 gelled 9 ...

New contraceptive methods: update 2003. -
A Pettinato, SJ Emans - Current Opinion in Pediatrics, 2003 - co-pediatrics.com
... available in print and on the Web [5??,6 ... index was 0.7 (95% CI, 0.31-1.10) [10 ...
Medroxyprogesterone acetate/estradiol cypionate injectable contraceptive TOP. ...

Source: Google Scholar
 

Injectable Drug Delivery Evolving As Protein Drugs For Chronic Conditions Proliferate

Article Date: 13 Mar 2007 - 0:00 PDT
As pharmaceutical companies struggle to position their products in the direct-to-consumer marketing era, the trend toward combining functionality and packaging in drug delivery systems is growing. Innovative drug delivery systems allow pharmaceutical companies to differentiate drug products from competitors. This is essential at a time when many patents are running out and competition among the manufacturers of generic medicines is increasing.

As patients live longer and are diagnosed with chronic and often debilitating ailments, the result will be a dramatic increase in self-administration of drug therapies in non-traditional settings for a number of conditions. This trend is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that new drug product success no longer only depends on the medication itself but also on achieving a patient-friendly form of application.

New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Reusable injectors designed to accept prefilled syringes or drug cartridges will improve ease-of-use and increase alternative device share of the growing self-injection market. Disposable prefilled models will penetrate selected practitioner segments such as wellness vaccines. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.

Article continues below and (thank you)

 
These findings are contained in a new and comprehensive report, Injectable Drug Delivery: Evolving Markets, Emerging Opportunities. Growth of alternative injection devices will be driven by a number of factors, including improved patient compliance and patient quality-of-care, and the trend toward drug therapy self-administration.

More information is available at http://www.greystoneassociates.org.

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
 

Mouse tests show stem cells treat brain disease

Last Updated: 2007-03-12 9:04:14 -0400 (Reuters Health)

WASHINGTON - Human stem cells taken from both embryos and fetuses delayed a fatal brain and nerve disease in mice, moving throughout the brain to take on the jobs of damaged neurons, scientists reported on Sunday.

They said their study, published in the journal Nature Medicine, represents the first time a human embryonic stem cell has successfully treated a disease in an animal.

Dr. Evan Snyder of the Burnham Institute for Medical Research in La Jolla, California, who led the study, says his team hopes to move quickly to test their method in children with a fatal and incurable brain disease called Sandhoff disease.

Writing in the journal Nature Medicine, they also said their approach could lead to ways to treat a range of neurodegenerative diseases such as Parkinson's, Alzheimer's and amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease.

For their study, Snyder and colleagues used mice bred with the equivalent of Sandhoff disease.

"Children with the disease have severe mental retardation and motor dysfunction, and death typically occurs in infancy," the researchers, who included a team at Oxford University in Britain, Yonsei University in Seoul, Korea and elsewhere, wrote in their report.

It is marked by inflammation that kills brain cells.

Snyder's team used both human embryonic stem cells, taken from days-old human embryos left over at fertility clinics, and human fetal stem cells.

They transplanted these into the brains of the mice and noted no problems. No tumors formed, the mice did not "reject" the foreign cells, and the treatment seemed to reduce inflammation.

"They just don't seem to get rejected," Snyder said.

BOOSTER SHOTS

The treated mice lived 70 percent longer than untreated mice. The disease eventually came back, but Snyder believes they could keep it at bay by giving booster injections of the stem cells to take over the functions of the mutated natural brain cells.

Stem cells are valued because they can give birth to a range of tissue and cell types. But Snyder said scientists are beginning to learn they do even more than this.

"This shows that stem cells engage in cross-talk," he said in a telephone interview.

"They collaborate ... to try to restore a system to balance. They secrete factors that are healthy. They try to restore the health of other cells and detoxify the system."

The transplanted human cells replaced damaged nerve cells and carried nerve signals. They also boosted the brain's supply of the enzyme hex, which is lacking in Sandhoff disease.

Sandhoff is caused by a mutation in the gene for an enzyme called hexosaminidase or hex, which brain cells need to get rid of excess fatty material called lipids.

When the lipids build up, brain cells die. It is similar to Tay-Sachs disease, and there is no treatment for either Tay-Sachs or Sandhoff.

The use of human embryonic stem cells is controversial because some people believe it is wrong to destroy human embryos in experiments.

Snyder said his team used batches of stem cells approved for funding by the U.S. government. He said when his team asks the U.S. Food and Drug Administration for permission to test the treatment on children, they will probably not seek to use the embryonic stem cells at first, but merely the fetal stem cells.

"I think they are a little bit squeamish," he said.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
Google
Web www.iconocast.com
 
 
Source for News : URL: http://www.medicalnewstoday.com and Reuters
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast